Form 4 for MNPR Monopar Therapeutics
Accepted 2022-04-01 00:00:00 ET · period of report 2022-03-31 · accession 0001654954-22-004490 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-01 | 2022-03-31 | MNPR | Mazar Andrew Paul | CSO, Dir | M - OptEx | — | +1,606 | 22.6K | +8% | — |
| D | 2022-04-01 | 2022-03-31 | MNPR | Mazar Andrew Paul | CSO, Dir | F - Tax | $2.55 | -471 | 22.1K | -2% | -$1,201 |
| D | 2022-04-01 | 2022-03-31 | MNPR | Mazar Andrew Paul | CSO, Dir | M - OptEx | $0.00 | -1,606 | 88.8K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | M | A | 1,606 | — | 22,595.80 | D | — | — | (F1) Represents shares acquired on vesting and settlement of restricted stock units. |
| 2 | Common | Common Stock | 2022-03-31 | F | D | 471 | $2.55 | 22,124.80 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2022-03-31 | M | D | 1,606 | $0.00 | 88,792 | D | — · — to — | 1,606 Common Stock | (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F4) On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |